beloc 5mg/5ml IV Injection

Metoprolol tartrate, the active ingredient in Beloc, has a blocking effect primarily on certain receptors in the heart (cardiac-specific beta-receptor blocker) and has a stress-shielding effect on the heart. This lowers blood pressure and improves cardiac function.

Beloc is used in adults

for cardiac arrhythmias with accelerated heartbeat (tachycardic cardiac arrhythmias)
for the acute treatment of a heart attack.
Use by syringe (parenteral use) is only intended for emergency cases and for hospital treatment.

Composition:
The active ingredient is: metoprolol tartrate. 1 ampoule contains 5 mg metoprolol tartrate.

– The other ingredients are: sodium chloride and water for injections.

Application:

Always use this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.

Beloc is used in adults.

Cardiac arrhythmias with accelerated heartbeat (tachycardic cardiac arrhythmias):

Initially, up to 5 mg metoprolol tartrate (equivalent to up to 5 ml) is administered slowly intravenously (1 – 2 mg/min.). If treatment is not successful, the injection can be repeated at intervals of 5 to 10 minutes until the effect occurs or until a total dose of 10 to 15 mg metoprolol tartrate (equivalent to 10 to 15 ml) is reached.

Acute treatment of a heart attack:

Beloc should be administered as soon as possible after stabilization of the patient’s circulation (hemodynamic stabilization) under constant cardiovascular monitoring (ECG and blood pressure monitoring).

At the start of treatment, 5 mg metoprolol tartrate (equivalent to 5 ml) is administered rapidly (as a bolus injection) intravenously.

Depending on tolerability, additional single doses of 5 mg metoprolol tartrate (equivalent to 5 ml) may be administered iv at intervals of 2 minutes up to a total dose of 15 mg metoprolol tartrate (equivalent to 15 ml).

If the full dose of 15 mg is tolerated, 50 mg of metoprolol tartrate is administered orally four times daily for the next 48 hours, starting 15 minutes after the last intravenous injection.

In patients who have tolerated less than 15 mg metoprolol tartrate intravenously, oral treatment should be started cautiously with 25 mg metoprolol tartrate.

Use in patients with impaired renal function

No dosage adjustment is necessary.

Use in patients with impaired liver function

If your liver function is severely impaired, your doctor will decide whether to adjust your dose.

Use in elderly patients (aged 65 and over)

No dosage adjustment is necessary.

Children and young people

The safety and efficacy of Beloc in children aged 0 to 18 years have not been established

Type of application

Intravenous administration of Beloc should be carried out slowly under constant cardiovascular monitoring (ECG and blood pressure control). If there is a drop in heart rate and/or blood pressure that requires treatment or if other complications occur, Beloc should be discontinued immediately.

When treating cardiac arrhythmias with accelerated heartbeat, it is recommended to continue treatment with tablets (as soon as the arrhythmias are under control).

Handling of OPC (one-point-cut) ampoules

The injection solution can contain a total amount of up to 40 mg metoprolol tartrate

(8 ampoules) should be added to 1000 ml of the following infusion solutions: sodium chloride 0.9%, mannitol 150 mg/ml, dextrose 100 mg/ml, dextrose 50 mg/ml, fructose 200 mg/ml, invert sugar 100 mg/ml, Ringer’s injection solution, Ringer’s dextrose and Ringer’s acetate.

If a large amount of Beloc has been used,
contact a doctor or hospital immediately. The doctor can decide on the necessary measures depending on the severity of the overdose or the type of symptoms.

The most common signs, depending on the severity of an overdose, are a sharp drop in blood pressure, slow pulse, irregular heartbeat, cardiac insufficiency, cardiovascular shock and cardiac arrest, as well as breathing difficulties with constriction/spasm of the airways, impaired consciousness, coma, nausea, vomiting, bluish discoloration of the skin and mucous membranes (cyanosis), hypoglycemia and seizures.

The symptoms may be aggravated by simultaneous intake of alcohol, other antihypertensive drugs, quinidine (for the treatment of cardiac arrhythmias) or barbiturates (sedatives).

Information for the doctor can be found at the end of this leaflet.